Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group

Bone Marrow Transplant. 1989 Dec:4 Suppl 3:36-7.

Authors

H H Gerhartz¹, G Visani, A Delmer, H Zwierzina, M Ribeiro, A Jacobs, R Marcus, M Baumelou, D Fière, B Labar, et al.

Affiliation

¹ Med. Dept. III, Klinikum Grosshadern, Munich University, FRG.

PMID: 2697397

No abstract available

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Adult
Aged
Aged, 80 and over
Colony-Stimulating Factors / administration & dosage*
Combined Modality Therapy
Cytarabine / administration & dosage*
Female
Granulocyte-Macrophage Colony-Stimulating Factor
Growth Substances / administration & dosage*
Humans
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / therapy
Randomized Controlled Trials as Topic

Substances

Colony-Stimulating Factors
Growth Substances
Cytarabine
Granulocyte-Macrophage Colony-Stimulating Factor